Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 160

1.

Avoiding immortal time bias in observational studies.

Raymakers AJN, Sadatsafavi M, Sin DD, FitzGerald JM, Marra CA, Lynd LD.

Eur Respir J. 2020 Mar 20;55(3). pii: 1902494. doi: 10.1183/13993003.02494-2019. Print 2020 Mar. No abstract available.

PMID:
32198270
2.

The Acute COPD Exacerbation Prediction Tool (ACCEPT): a modelling study.

Adibi A, Sin DD, Safari A, Johnson KM, Aaron SD, FitzGerald JM, Sadatsafavi M.

Lancet Respir Med. 2020 Mar 13. pii: S2213-2600(19)30397-2. doi: 10.1016/S2213-2600(19)30397-2. [Epub ahead of print]

PMID:
32178776
3.

Response.

Chen W, Sin DD, Sadatsafavi M.

Chest. 2020 Mar;157(3):738-739. doi: 10.1016/j.chest.2019.10.058. No abstract available.

PMID:
32145813
4.

Effects of β2-Adrenergic Agonists on Risk of Parkinson's Disease in COPD: a population-based study.

Chen W, Sadatsafavi M, Tavakoli H, Samii A, Etminan M.

Pharmacotherapy. 2020 Mar 7. doi: 10.1002/phar.2383. [Epub ahead of print]

PMID:
32145705
5.

Validation and Utility Testing of Clinical Prediction Models: Time to Change the Approach.

Adibi A, Sadatsafavi M, Ioannidis JPA.

JAMA. 2020 Mar 5. doi: 10.1001/jama.2020.1230. [Epub ahead of print] No abstract available.

PMID:
32134437
6.

Effects of long-term inhaled corticosteroid treatment on fragility fractures in older women: the Manitoba BMD registry study.

Ng BC, Leslie WD, Johnson KM, FitzGerald JM, Sadatsafavi M, Chen W.

Osteoporos Int. 2020 Mar 2. doi: 10.1007/s00198-020-05361-9. [Epub ahead of print]

PMID:
32123939
7.

A threshold-free summary index for quantifying the capacity of covariates to yield efficient treatment rules.

Sadatsafavi M, Mansournia MA, Gustafson P.

Stat Med. 2020 Jan 30. doi: 10.1002/sim.8481. [Epub ahead of print]

PMID:
31998998
8.

Looking at the COPD spectrum through "PRISm".

Adibi A, Sadatsafavi M.

Eur Respir J. 2020 Jan 2;55(1). pii: 1902217. doi: 10.1183/13993003.02217-2019. Print 2020 Jan. No abstract available.

PMID:
31896682
9.

Vitamin D in the prevention of exacerbations of asthma in preschoolers (DIVA): protocol for a multicentre randomised placebo-controlled triple-blind trial.

Jensen ME, Ducharme FM, Alos N, Mailhot G, Mâsse B, White JH, Sadatsafavi M, Khamessan A, Tse SM, Alizadehfar R, Bock DE, Daigneault P, Lemire C, Yang C, Radhakrishnan D.

BMJ Open. 2019 Dec 30;9(12):e033075. doi: 10.1136/bmjopen-2019-033075.

10.

Cost-effectiveness of implementing objective diagnostic verification of asthma in the United States.

Yaghoubi M, Adibi A, Zafari Z, FitzGerald JM, Aaron SD, Johnson KM, Sadatsafavi M.

J Allergy Clin Immunol. 2019 Dec 11. pii: S0091-6749(19)31634-3. doi: 10.1016/j.jaci.2019.11.038. [Epub ahead of print]

11.

Baseline characteristics and comorbidities in the CAnadian REgistry for Pulmonary Fibrosis.

Fisher JH, Kolb M, Algamdi M, Morisset J, Johannson KA, Shapera S, Wilcox P, To T, Sadatsafavi M, Manganas H, Khalil N, Hambly N, Halayko AJ, Gershon AS, Fell CD, Cox G, Ryerson CJ.

BMC Pulm Med. 2019 Nov 27;19(1):223. doi: 10.1186/s12890-019-0986-4.

12.

Healthcare system encounters before COPD diagnosis: a registry-based longitudinal cohort study.

Johnson KM, Khakban A, Bryan S, Sin DD, Sadatsafavi M.

Thorax. 2020 Feb;75(2):108-115. doi: 10.1136/thoraxjnl-2019-213554. Epub 2019 Nov 8.

PMID:
31704794
13.

Direct costs of overdiagnosed asthma: a longitudinal, population-based cohort study in British Columbia, Canada.

Ng B, Sadatsafavi M, Safari A, FitzGerald JM, Johnson KM.

BMJ Open. 2019 Nov 7;9(11):e031306. doi: 10.1136/bmjopen-2019-031306.

14.

Triple therapy in a single inhaler: a new option for uncontrolled asthma.

FitzGerald JM, Sadatsafavi M.

Lancet. 2019 Nov 9;394(10210):1690-1692. doi: 10.1016/S0140-6736(19)32216-0. Epub 2019 Sep 30. No abstract available.

PMID:
31582315
15.

Trends in prescriptions and costs of inhaled medications in chronic obstructive pulmonary disease: a 19-year population-based study from Canada.

Tavakoli H, Johnson KM, FitzGerald JM, Sin DD, Gershon AS, Kendzerska T, Sadatsafavi M.

Int J Chron Obstruct Pulmon Dis. 2019 Sep 3;14:2003-2013. doi: 10.2147/COPD.S210897. eCollection 2019.

16.

An Individualized Prediction Model for Long-term Lung Function Trajectory and Risk of COPD in the General Population.

Chen W, Sin DD, FitzGerald JM, Safari A, Adibi A, Sadatsafavi M.

Chest. 2020 Mar;157(3):547-557. doi: 10.1016/j.chest.2019.09.003. Epub 2019 Sep 19.

PMID:
31542453
17.

Economic burden of multimorbidity in patients with severe asthma: a 20-year population-based study.

Chen W, Safari A, FitzGerald JM, Sin DD, Tavakoli H, Sadatsafavi M.

Thorax. 2019 Dec;74(12):1113-1119. doi: 10.1136/thoraxjnl-2019-213223. Epub 2019 Sep 18.

PMID:
31534029
18.

A Systematic Review of Decision-Analytic Models for Evaluating Cost-Effectiveness of Asthma Interventions.

Ehteshami-Afshar S, Zafari Z, Hamidi N, FitzGerald JM, Lynd L, Sadatsafavi M.

Value Health. 2019 Sep;22(9):1070-1082. doi: 10.1016/j.jval.2019.03.016. Epub 2019 May 23. Review.

PMID:
31511184
19.

Socioeconomic status at diagnosis influences the incremental direct medical costs of systemic lupus erythematosus: A longitudinal population-based study.

McCormick N, Marra CA, Sadatsafavi M, Aviña-Zubieta JA.

Semin Arthritis Rheum. 2020 Feb;50(1):77-83. doi: 10.1016/j.semarthrit.2019.06.010. Epub 2019 Jun 14.

PMID:
31358362
20.

Transparency in Decision Modelling: What, Why, Who and How?

Sampson CJ, Arnold R, Bryan S, Clarke P, Ekins S, Hatswell A, Hawkins N, Langham S, Marshall D, Sadatsafavi M, Sullivan W, Wilson ECF, Wrightson T.

Pharmacoeconomics. 2019 Nov;37(11):1355-1369. doi: 10.1007/s40273-019-00819-z. Review.

PMID:
31240636
21.

The Projected Economic and Health Burden of Uncontrolled Asthma in the United States.

Yaghoubi M, Adibi A, Safari A, FitzGerald JM, Sadatsafavi M.

Am J Respir Crit Care Med. 2019 Nov 1;200(9):1102-1112. doi: 10.1164/rccm.201901-0016OC.

22.

Costs of Workplace Productivity Loss in Patients With Fibrotic Interstitial Lung Disease.

Algamdi M, Sadatsafavi M, Fisher JH, Morisset J, Johannson KA, Fell CD, Kolb M, Manganas H, Cox G, Gershon AS, Halayko AJ, Hambly N, Khalil N, Shapera S, To T, Wilcox PG, Guler S, Ryerson CJ.

Chest. 2019 Nov;156(5):887-895. doi: 10.1016/j.chest.2019.04.016. Epub 2019 Apr 30.

23.

Lowering the P Value Threshold.

Adibi A, Sin D, Sadatsafavi M.

JAMA. 2019 Apr 16;321(15):1532-1533. doi: 10.1001/jama.2019.0566. No abstract available.

PMID:
30990544
24.

Precision health: treating the individual patient with chronic obstructive pulmonary disease.

Obeidat M, Sadatsafavi M, Sin DD.

Med J Aust. 2019 May;210(9):424-428. doi: 10.5694/mja2.50138. Epub 2019 Apr 11. Review.

PMID:
30977152
25.

Inhaled corticosteroids and the risk of lung cancer in COPD: a population-based cohort study.

Raymakers AJN, Sadatsafavi M, Sin DD, FitzGerald JM, Marra CA, Lynd LD.

Eur Respir J. 2019 Jun 5;53(6). pii: 1801257. doi: 10.1183/13993003.01257-2018. Print 2019 Jun.

PMID:
30956205
26.

Cost-effectiveness of Latent Tuberculosis Infection Screening before Immigration to Low-Incidence Countries.

Campbell JR, Johnston JC, Cook VJ, Sadatsafavi M, Elwood RK, Marra F.

Emerg Infect Dis. 2019 Apr;25(4):661-671. doi: 10.3201/eid2504.171630.

27.

Extent, trends, and determinants of controller/reliever balance in mild asthma: a 14-year population-based study.

Khakban A, FitzGerald JM, Tavakoli H, Lynd L, Ehteshami-Afshar S, Sadatsafavi M.

Respir Res. 2019 Feb 28;20(1):44. doi: 10.1186/s12931-019-1007-0.

28.

Use of biologics during pregnancy and risk of serious infections in the mother and baby: a Canadian population-based cohort study.

Tsao NW, Lynd LD, Sayre EC, Sadatsafavi M, Hanley G, De Vera MA.

BMJ Open. 2019 Feb 20;9(2):e023714. doi: 10.1136/bmjopen-2018-023714.

29.

Introduction to precision medicine in COPD.

Leung JM, Obeidat M, Sadatsafavi M, Sin DD.

Eur Respir J. 2019 Apr 11;53(4). pii: 1802460. doi: 10.1183/13993003.02460-2018. Print 2019 Apr.

PMID:
30679189
30.

Development and Validation of the Evaluation Platform in COPD (EPIC): A Population-Based Outcomes Model of COPD for Canada.

Sadatsafavi M, Ghanbarian S, Adibi A, Johnson K, FitzGerald JM, Flanagan W, Bryan S, Sin D; Canadian Respiratory Research Network.

Med Decis Making. 2019 Feb;39(2):152-167. doi: 10.1177/0272989X18824098. Epub 2019 Jan 24.

PMID:
30678520
31.

Heterogeneity in the respiratory symptoms of patients with mild-to-moderate COPD.

Johnson KM, Safari A, Tan WC, Bourbeau J, FitzGerald JM, Sadatsafavi M, Study OBOTCCOOLDC; Canadian Respiratory Research Network.

Int J Chron Obstruct Pulmon Dis. 2018 Dec 13;13:3983-3995. doi: 10.2147/COPD.S184424. eCollection 2018.

32.

Making sense of cost-effectiveness analyses in respiratory medicine: a practical guide for non-health economists.

van Boven JFM, van de Hei SJ, Sadatsafavi M.

Eur Respir J. 2019 Mar 7;53(3). pii: 1801816. doi: 10.1183/13993003.01816-2018. Print 2019 Mar. No abstract available.

PMID:
30578398
33.

A systematic review of the adverse events and economic impact associated with oral corticosteroids in asthma.

Al Efraij K, Johnson KM, Wiebe D, Sadatsafavi M, FitzGerald JM.

J Asthma. 2019 Dec;56(12):1334-1346. doi: 10.1080/02770903.2018.1539100. Epub 2018 Dec 4.

PMID:
30513226
34.

Long-term effects of inhaled corticosteroids on bone mineral density in older women with asthma or COPD: a registry-based cohort study.

Chen W, Johnson KM, FitzGerald JM, Sadatsafavi M, Leslie WD.

Arch Osteoporos. 2018 Oct 29;13(1):116. doi: 10.1007/s11657-018-0537-2.

PMID:
30374631
35.

Screening for Latent Tuberculosis Infection in Migrants With CKD: A Cost-effectiveness Analysis.

Campbell JR, Johnston JC, Ronald LA, Sadatsafavi M, Balshaw RF, Cook VJ, Levin A, Marra F.

Am J Kidney Dis. 2019 Jan;73(1):39-50. doi: 10.1053/j.ajkd.2018.07.014. Epub 2018 Sep 28.

PMID:
30269868
36.

Relative impact characteristic curve: a graphical tool to visualize and quantify the clinical utility and population-level consequences of implementing markers.

Sadatsafavi M, Gustafson P, Zafari Z, Sin DD.

Ann Epidemiol. 2018 Oct;28(10):717-723.e3. doi: 10.1016/j.annepidem.2018.07.014. Epub 2018 Jul 30.

37.

The diagnostic performance of patient symptoms in screening for COPD.

Johnson KM, Tan WC, Bourbeau J, Sin DD, Sadatsafavi M; Canadian Cohort of Obstructive Lung Disease (CanCOLD) study and the Canadian Respiratory Research Network.

Respir Res. 2018 Aug 3;19(1):147. doi: 10.1186/s12931-018-0853-5.

38.

Asthma is not associated with the need for surgery in Crohn's disease when controlling for smoking status: a population-based cohort study.

Kuenzig ME, Sadatsafavi M, Aviña-Zubieta JA, Burne RM, Abrahamowicz M, Beauchamp ME, Kaplan GG, Benchimol EI.

Clin Epidemiol. 2018 Jul 12;10:831-840. doi: 10.2147/CLEP.S156772. eCollection 2018.

39.

Long-Term Trajectories of Mild Asthma in Adulthood and Risk Factors of Progression.

Chen W, FitzGerald JM, Lynd LD, Sin DD, Sadatsafavi M.

J Allergy Clin Immunol Pract. 2018 Nov - Dec;6(6):2024-2032.e5. doi: 10.1016/j.jaip.2018.04.027. Epub 2018 May 7.

PMID:
29746917
40.

The projected economic and health burden of sub-optimal asthma control in Canada.

Zafari Z, Sadatsafavi M, Chen W, FitzGerald JM.

Respir Med. 2018 May;138:7-12. doi: 10.1016/j.rmed.2018.03.018. Epub 2018 Mar 16.

PMID:
29724396
41.

Incremental direct medical costs of systemic lupus erythematosus patients in the years preceding diagnosis: A general population-based study.

McCormick N, Marra CA, Sadatsafavi M, Aviña-Zubieta JA.

Lupus. 2018 Jul;27(8):1247-1258. doi: 10.1177/0961203318768882. Epub 2018 Apr 17.

PMID:
29665755
42.

Excess Productivity Costs of Systemic Lupus Erythematosus, Systemic Sclerosis, and Sjögren's Syndrome: A General Population-Based Study.

McCormick N, Marra CA, Sadatsafavi M, Kopec JA, Aviña-Zubieta JA.

Arthritis Care Res (Hoboken). 2019 Jan;71(1):142-154. doi: 10.1002/acr.23573.

43.

The Impact of Care Specialty on Survival-Adjusted Medical Costs of COPD Patients After a Hospitalization: a longitudinal analysis.

Chen W, Sin DD, FitzGerald JM, Sadatsafavi M; Canadian Respiratory Research Network.

J Gen Intern Med. 2018 Sep;33(9):1528-1535. doi: 10.1007/s11606-018-4406-x. Epub 2018 Apr 2.

44.

Risk of preterm delivery and small-for-gestational-age births in women with autoimmune disease using biologics before or during pregnancy: a population-based cohort study.

Tsao NW, Sayre EC, Hanley G, Sadatsafavi M, Lynd LD, Marra CA, De Vera MA.

Ann Rheum Dis. 2018 Jun;77(6):869-874. doi: 10.1136/annrheumdis-2018-213023. Epub 2018 Mar 1.

PMID:
29496718
45.

The effect of text messaging on latent tuberculosis treatment adherence: a randomised controlled trial.

Johnston JC, van der Kop ML, Smillie K, Ogilvie G, Marra F, Sadatsafavi M, Romanowski K, Budd MA, Hajek J, Cook V, Lester RT.

Eur Respir J. 2018 Feb 7;51(2). pii: 1701488. doi: 10.1183/13993003.01488-2017. Print 2018 Feb.

46.

Predictors of inappropriate and excessive use of reliever medications in asthma: a 16-year population-based study.

Tavakoli H, Mark FitzGerald J, Lynd LD, Sadatsafavi M.

BMC Pulm Med. 2018 Feb 12;18(1):33. doi: 10.1186/s12890-018-0598-4.

47.

Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US.

Zafari Z, Sadatsafavi M, Mark FitzGerald J; Canadian Respiratory Research Network.

Cost Eff Resour Alloc. 2018 Jan 30;16:3. doi: 10.1186/s12962-018-0089-8. eCollection 2018.

48.

Characterizing undiagnosed chronic obstructive pulmonary disease: a systematic review and meta-analysis.

Johnson KM, Bryan S, Ghanbarian S, Sin DD, Sadatsafavi M.

Respir Res. 2018 Feb 7;19(1):26. doi: 10.1186/s12931-018-0731-1. Review.

49.

Response.

Raymakers AJN, Sadatsafavi M, Sin DD, De Vera MA, Lynd LD.

Chest. 2018 Feb;153(2):578-579. doi: 10.1016/j.chest.2017.12.006. No abstract available.

PMID:
29406228
50.

The association between previous and future severe exacerbations of chronic obstructive pulmonary disease: Updating the literature using robust statistical methodology.

Sadatsafavi M, Xie H, Etminan M, Johnson K, FitzGerald JM; Canadian Respiratory Research Network.

PLoS One. 2018 Jan 19;13(1):e0191243. doi: 10.1371/journal.pone.0191243. eCollection 2018.

Supplemental Content

Loading ...
Support Center